Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE

Date Title and Summary
Toggle Summary Biosite and FivePrime Announce Antibody Collaboration
Biosite and FivePrime Announce Antibody Collaboration SAN DIEGO and SAN FRANCISCO—Biosite® Incorporated  (Nasdaq: BSTE) and Five Prime Therapeutics, Inc. have entered into a collaboration for the evaluation of disease targets for potential commercialization of diagnostic and therapeutic products.
Toggle Summary FivePrime and Boehringer Ingelhein Initiate Rheumatoid Arthritis Collaboration
FivePrime and Boehringer Ingelhein Initiate Rheumatoid Arthritis Collaboration San Francisco - Five Prime Therapeutics, Inc. announced today to have entered into a two year collaborative research and license agreement with Boehringer Ingelheim to discover novel therapeutic products to treat

Upcoming and Recent Events > MORE

Date Event Details
Summary Toggle Thursday, June 14, 2018 8:00 AM PDT
Summary Toggle Thursday, June 07, 2018 11:00 AM EDT

Speaker

Francis Sarena
Chief Strategy Officer and Secretary

Supporting Materials

Summary Toggle Tuesday, May 08, 2018 4:30 PM EDT